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Background: Regulatory T cells (Tregs) are required for proper maintenance of immunological self-tolerance and
immune homeostasis. Folate receptor 4 (FR4) is expressed at high levels in transforming growth factor-beta (TGF-β)-
induced Tregs and natural Tregs. Moreover, antibody-mediated targeting of FR4 is sufficient to mediate Treg
depletion.
Results: In this study, we describe a novel FR4 transcript variant, FR4D3, in which exon 3 is deleted. The mRNA of
FR4D3 encodes a FR4 variant truncated by 189 bp. FR4D3 was found to be predominantly expressed in CD4+CD25+
Treg cells. Overexpression of FR4D3 in CD4+CD25+ Treg cells in vitro stimulated proliferation, which may modulate
the ability of these cells to bind and incorporate folic acid.
Conclusions: Our results suggested that high levels of FR4D3 may be critical to support the substantial proliferative
capacity of Treg cells.
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The folate receptor (FR), also known as the folic acid
(FA) binding protein, is responsible for binding of 5-
methyltetrahydrofolate (5-MeTHF) with high affinities
(~100 pM Kd), thereby playing an important role in the
uptake of serum folates by cells expressing this receptor
[1,2]. Four isoforms of the human FR, FR-α, -β, -γ and
–δ, have been identified and characterized. FR-α is pre-
dominantly expressed on epithelial cells [3,4]. FR-β is
expressed only on activated macrophages and the sur-
faces of malignant cells of hematopoietic origin [5]. FR-γ
was identified as a secretory protein from hematopoietic
tissues, and demonstrated to have a much lower affinity
for FA than FR-α [6,7]. FR-δ has proven difficult to de-
tect in human tissues, suggesting a highly restricted
spatial/temporal expression pattern, presence of a
pseudogene, or predominance of an alternatively spliced
variant [8]. Recent data, however, has indicated that FR-
δ may be expressed on regulatory T cells (Tregs) [9].* Correspondence: wuyuzhang@yahoo.com; nibingxi@yahoo.com
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reproduction in any medium, provided the orAnalysis of amino acid sequences in the mouse led to
the identification of homologues of human FR-α and
FR-β, known as folic acid-binding protein 1 and 2
(Folbp1/FR1 and Folbp2/FR2) [10]. Utilizing a ‘genome
database mining’ strategy, Spiegelstein et al. identified a
third murine FR, Folbp3 (also called FR4), which is
highly homologous to human FR-δ [8,11]. In addition to
regulating FA uptake, FR4 has been hypothesized to play
a potential role in immune responses based upon its ex-
pression profile, which includes spleen- and thymus-
related lymphoid tissues and lymphocytes [8]. Indeed,
FR4 has been demonstrated to be exclusively expressed
in splenic lymphocytes, especially in the T lymphocytes,
and in mature thymocytes; however, few studies have
reported on the characterization of FR4 [8,11].
Tregs are required for proper maintenance of im-
munological self-tolerance and immune homeostasis
[12]. Studies to identify molecular markers of Tregs
determined that FR4 is expressed at particularly high
amounts in natural (n)Tregs and plays an important role
in the maintenance of the Treg phenotype [13]. In our
previous study, we identified a FR4 cDNA splice variant
(FR4v) with intron 3 (108 bp) retained from the FR4
gene and confirmed protein expression of this variant. This is an Open Access article distributed under the terms of the Creative
ommons.org/licenses/by/2.0), which permits unrestricted use, distribution, and
iginal work is properly cited.
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transcript variant, named FR4D3, with the full-length
exon 3 (189 bp) deleted. The FR4D3-encoded protein
was confirmed to be expressed on CD4+CD25+ Tregs by
Western blotting and fluorescence-activated cell sorting
(FACS) assays. Finally, the role of the FR4D3 variant was
investigated by overexpression in Treg cells in vitro.
Methods
Isolation of RNA, amplification and cloning of FR4D3
Six to eight-week-old female BALB/c mice were pur-
chased from the Animal Center at the Chinese Academy
of Medical Science(CAMS) branch in Beijing, China. All
animals were maintained in pathogen-free conditions.
All of the animal studies were approved by the Institu-
tional Animal Care and Use Committee of the Third
Military Medical University.
Total RNA was extracted from BALB/c mouse spleno-
cytes using the TRIzolW reagent (Invitrogen, USA)
according to the manufacturer's instructions. Approxi-
mately 1 μg of total RNA was reverse transcribed to
cDNA using the High Fidelity PrimeScript™ reverse
transcription-polymerase chain reaction (RT-PCR) kit
(TaKaRa, Japan). The cDNA was then used as template
to PCR amplify the FR4 coding DNA sequence (CDS)
with the following primers corresponding to the ends of
exons 2 and 5 of the mouse FR4 gene, respectively:
mFR4-F, 5'-ATGGCACAGTGGTGGCAGAT-3'; mFR4-
R, 5'-TCAGG GATGGAACAACAGGC-3'. The PCR re-
action was carried out under the following thermal cyc-
ling conditions: 30 cycles of 98°C for 10 s and 68°;C for
40 s. The PCR amplicons were then subcloned into the
pMD19-T vector (TaKaRa), and the clones were fully
sequenced at Shanghai Sangon Biological Engineering
Technology & Services Co., Ltd (China). The mRNA ex-
pression of FR4, FR4v and FR4D3 genes in splenocytes,
CD4+ T cells, and CD4+CD25+ T cells were detected
using RT-PCR assays with the following primers: 5'-
GGGACAAACTGCTCAGCGTCT-3' (forward) and 5'-
AGACACCGCCCACTGTTCCT-3' (reverse).
To construct FR4- or FR4D3-expressing recombinant
plasmids, the FR4 or FR4D3 coding sequence was PCR-
amplified from BALB/c mouse splenocytes RNA and
cloned directly into the pCI-neo vector (Promega, USA).
The following primers were used: Forward primer: 5'-
CCGCTCGAGGCCACCATGGCACAGTGGTGGCA-
GAT-3'; Reverse primer: 5'-CGTGGGTGCTCTAGAT-
CAGGGATGGAACAACAGGC-3'.
FACS analysis
Approximately 1 × 108 splenocytes were stained with
anti-CD4-FITC, anti-CD25-PE and anti-CD8- PerCP-
Cy5.5 antibodies (all from eBioscience, USA). The
stained cells were separated by FACS into batches ofCD4+CD25+ T cells, CD4+CD25- T cells, and CD8+ T
cells with a FACS-Aria high-speed cell sorter (BD Bios-
ciences, USA). The isolated CD4+CD25+ T cells were
stained with intracellular anti-FOXP3-APC antibody
(eBioscience, USA) and then detected by the FACS-Aria
high-speed cell sorter.
Western blotting analysis
Isolated splenocytes and T cell subsets CD4+CD25–,
CD4+CD25+, or CD8+ were lysed with the T-PERW Tis-
sue Protein Extraction Reagent (Pierce, USA) at room
temperature. After 5 min of lysis, the cell debris was
removed via centrifugation at 12,000 rpm for 5 min at
4°;C and the lysates were treated with N-glycosidase be-
fore blotting [15]. The protein-containing supernatant
was mixed with 4 × nonreducing lithium dodecyl sulfate
(LDS) sample buffer (Invitrogen) and heated for 10 min
at 70°;C. The protein samples (10–50 μg) were resolved
by electrophoresis through NuPAGEW Novex 10% Bis-
Tris mini-gels (Invitrogen) and transferred onto a polyvi-
nylidene fluoride (PVDF) membrane (Millipore, Ger-
many). After blocking of non-specific sites, the
membranes were incubated with primary antibody
(1:1,000 rat anti-mouse FR4; Abcam, United Kingdom)
at 4°;C overnight, followed by incubation with secondary
antibody (1:10,000 goat anti-rat IgG; Abcam) for 1 h.
Immunoreactive bands were observed using the
enhanced chemiluminescence (ECL) detection reagents
(Amersham Biosciences, United Kingdom), according to
the manufacturer’s instructions. β-actin was detected as
an internal control (primary antibody: rabbit anti-mouse
β-actin, secondary antibody: goat anti-rabbit IgG; both
from Abcam).
The pCI-neo-FR4 or pCI-neo-FR4D3 vector (0.5 μg)
was added to 2 × 104 FACS-sorted CD4+CD25+ Tregs
resuspended in 100 μL of mouse T cell Nucleofector so-
lution and electroporated using the 96-DN-100 program
on the Nucleofector instrument (Lonza, Germany). After
24 h of culture in serum-free conditions, the expressions
of FR4 and FR4D3 proteins in the respective transfected
cells were analyzed with Western blotting assay using
anti-mouse FR4 (Abcam) as the primary antibody. The
immunoreactive bands were scanned and densitometric
analysis was performed by Bio-Rad Quantity One
software.
Proliferation assays
The FACS-sorted CD4+CD25+ Tregs were stimulated
with various concentrations of FA (0, 2, 4, 6, 8, 10 ng/
mL; Sigma-Aldrich, USA) in the presence of interleukin
(IL)-2 (300 U/mL; R&D Systems, USA), anti-CD3 (5 μg/
mL; BD Biosciences)/anti-CD28 (2 μg/mL; BD Bios-
ciences) (pre-coated and soluble, respectively). Cultures
were incubated for three days and labeled with 0.5 μCi
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lytics, Germany) during the last 18 hours of incubation.
[3H]TdR incorporation was measured by a liquid scintil-
lation counter (Top Count; Perkin Elmer, Germany). All
assays were performed in triplicate.
The CD4+CD25+ Tregs transfected with pCI-neo-FR4
or pCI-neo-FR4D3 plasmids were seeded in 96-well U-
bottom plates pre-coated with anti-CD3(5 μg/mL) and
co-stimulated for three days with soluble anti-CD28 (2
μg/mL), with or without IL-2 (300 U/mL) or FA (4, ng/
mL). During the last 18 hours of culture, cells were la-
beled with 0.5 μCi (0.0185 MBq) [3H]thymidine. [3H]
thymidine incorporation was measured by a liquid scin-
tillation counter. All assays were performed in triplicate.
Statistical analysis
Relative comparisons of FR4 and FR4D3 proteins’ inten-
sity abundance between the transfected cells and
untransfected cells detected by Western blot assay and
the differences in proliferation of sorted CD4+CD25+
Tregs were analyzed by means of the 2-tailed Student’s
t-test. P-values less than 0.05 were considered
significant.
Results
Identification of a novel FR4 isoform
When we amplified the full-length FR4 CDS from mur-
ine splenocytes by RT-PCR with the primer pair mFR4-F
and mFR4-R (Figure 1A), three distinctive transcripts
were amplified. The sizes of the two largest transcripts
corresponded to the full-length FR4 (735 bp) and the
variant FR4v (843 bp) [14]; however, the third transcript
appeared to be a truncated form of FR4 (546 bp)
(Figure 1B). The 546 bp PCR product was isolated,
cloned and sequenced. Results showed that the 546 bp
band’s sequence was almost identical to the FR4 CDS,
except with 189 bp of contiguous sequence deleted.
Alignment analysis with FR4 mRNA sequence revealed
that the missing 189 bp sequence corresponded to the
entire exon 3 of the reported FR4 mRNA (Figure 1C).
This newly identified splice variant of the FR4 gene was
designated as FR4D3. Furthermore, the results indicated
that the mature mRNAs of FR4D3, FR4v, and FR4 were
generated from the same pro-mRNA. We then investi-
gated the mRNA expression of FR4 gene variants in
splenocytes, CD4+ T cells, and CD4+CD25+ T cells, re-
spectively. The RT-PCR assays revealed that all FR4 var-
iants were expressed in these cell types, but the relative
abundance of FR4D3 was lower than the other variants
(Figure 1D).
Since the 189 bp-length exon 3 is composed of exactly
63 triplet codes of the FR4 mRNA, its elimination will
not change the correct translation of FR4D3 mRNA.
Therefore, Western blotting assay was used to determinewhether the FR4D3 protein was expressed in mouse
spleen cells. As shown in Figure 1E, the anti-FR4 anti-
body detected both the full-length FR4 and the trun-
cated FR4D3 variant in mouse splenocytes, whose
predicted molecular masses were approximately 28 kDa
and 21 kDa, respectively. The sequence and theoretical
translation of this novel cDNA were submitted to Gen-
Bank and can be found under accession numbers
EU326439.1 and ABY56299.1, respectively.
Predominant expression of FR4D3 in CD4+CD25+
regulatory T cells
It has been reported that natural Treg cells constitutively
express higher amounts of FR4 [13]. In order to examine
whether the FR4D3 exhibits a differential distribution in
T cell subpopulations, high purity populations of specific
T cell subtypes were obtained by FACS sorting. The pur-
ity of isolated CD8+, CD4+CD25–, and CD4+CD25+ T
cells reached 99.3%, 99.0%, and 98.3%, respectively
(Figure 2A). After sorting, we detected the purity of
Foxp3-positive cells in the isolated CD4+CD25+ T cells
and found that the Foxp3-positive cells reached ~91%,
suggesting that most of the isolated CD4+CD25+ T cells
were Tregs (Figure 2B). Western blotting analysis of
these subtypes showed that FR4 and FR4D3 proteins
were expressed in CD4+CD25+ Tregs at a higher level
than in either CD4+CD25- or CD8+ T cells (Figure 2C).
These results suggested that FR4D3 may play a redun-
dant or unique functional role in CD4+CD25+ Tregs.
Effect of overexpression of FR4D3 on proliferation of CD4
+CD25+ T cells
The capacity to efficiently bind and incorporate folic
acid is linked to cellular proliferation, and indeed over-
expression of folate receptors is a characteristic feature
of certain tumors [16]. It has been reported that FR4 is
not merely a marker of natural Treg cells but is also
functionally essential for their maintenance since block-
ade of FR4 was sufficient to reduce natural Treg cells
in vivo [13]. In order to investigate the function of FR4
and FR4D3, we respectively overexpressed each in the
isolated CD4+CD25+ Tregs. Results showed that the
level of FR4 or FR4D3 protein was much higher in trans-
fected cells than in untransfected cells (Figure 3A). We
then examined the proliferative ability of FACS-sorted
CD4+CD25+ Tregs in response to stimulation with FA,
in the presence of IL-2, anti-CD3/anti-CD28 (pre-coated
and soluble, respectively) in vitro. Results should that
only simultaneous stimulation with anti-CD3/anti-CD28
in the presence of IL-2 could abrogate the anergic state
of CD4+CD25+ Tregs. Moreover, the proliferative ability
of these cells was further enhanced by addition of FA to
the stimulation mixture in a dose-response manner
(Figure 3B), and FA mediated more proliferation than
Figure 1 Identification of a novel truncated FR4 variant from BALB/c mouse splenocytes. (A) Schematic diagram of the mouse FR4 gene.
Exons are indicated by solid lines, and introns by dashed lines. Positions of primers used for PCR amplification are shown by arrows. (B) RT-PCR
detection of full-length CDS of FR4 and FR4D3 genes in mouse splenocytes. (C) RT-PCR detection of FR4 and FR4D3 mRNA in splenocytes, CD4+ T
cells, and CD4+CD25+ T cells. (D) The nucleotide and predicted amino acid sequences of the novel mouse FR4D3 CDS. The 189 bp exon 3 was
deleted and did not cause frame shift mutation. The exons are indicated in bold and the exon-exon junction sites are indicated by arrows. (E)
Western blotting assay showing FR4 and FR4D3 proteins detected by rat anti-mouse FR4 monoclonal antibody (mAb). Here, 50 μg splenocyte
lysates were treated with N-glycosidase before blotting [15].
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However, the proliferation capacity of cells induced with
FA+ IL-2 + anti-CD3/anti-CD28 was even further en-
hanced by overexpression of FR4 or FR4D3 (Figure 3C),
indicating that both receptors have a substantial capacity
to uptake the FA substrate. The wild-type (Wt) FR4
appeared to have stronger ability to uptake FA than theFR3D3 variant since overexpression of the former
showed higher proliferative capacity in the presence of
the FA substrate (Figure 3C).
Discussion
In this study, we have identified a novel alternative spli-
cing variant of the FR4 gene, named FR4D3, which lacks
Figure 2 Expression of the novel FR4D3 variant in splenic T cell sub populations. (A) Isolation and purity (%) of splenic T cell
subpopulations. (B) Purity of Foxp3-positive cells in isolated CD4+CD25+ T cells. (C) FR4D3 protein expression in particular T cell subsets was
detected by Western blotting assay using anti-mouse FR4 mAb . Here, 10 μg of total cell extracts was treated with N-glycosidase before blotting.
β-actin protein was detected as an internal control.
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found to be expressed in CD4+CD25+ Tregs at a higher
level than in CD4+CD25- or CD8+ T cells. Furthermore,
overexpression of FR4D3 in FACS-sorted CD4+CD25+
Tregs was found to enhance proliferative capacity of
these cells in vitro.
Recent studies have demonstrated that nearly every
multi-exon gene, including “constitutively” spliced genes
[17], produces alternative mRNA isoforms [18]. Al-
though many of these isoforms have importantfunctional roles, it is clear that some of these mRNAs
are produced by errors that occur during the splicing
process [19]. In fact, different RNA quality controls have
evolved to recognize and degrade such errors. For those
mRNAs that escape detection and destruction, expres-
sion may be at such low levels that the new mRNA
isoforms may be tolerated by the cell, eventually repre-
senting an evolutionary precursor [20,21].
Previous studies have suggested that FR4 is exclusively
expressed by splenic lymphocytes, especially the T
Figure 3 Proliferation of sorted CD4+CD25+ Tregs. (A) Overexpression of FR4 or FR4D3 protein in sorted CD4+CD25+ Tregs. Wt, wild type cells;
Over-FR4, overexpression of FR4; Over-FR4D3, overexpression of FR4D3. Each column represents the intensity abundance ratio of the FR4 or
FR4D3 band versus the actin band in each lane. Panels show a representative of three independent experiments. Error bars represent the
standard deviation from three independent experiments. *, P< 0.05, vs. wild type cells. (B) FA dose-response of Tregs’ proliferation. The CD4
+CD25+ Tregs were stimulated with various concentrations of FA (0, 2, 4, 6, 8, 10 ng/mL) in the presence of IL-2, anti-CD3/anti-CD28 (pre-coated
and soluble, respectively). Panels show a representative of three independent experiments. Error bars represent the standard deviation from
triplicate wells.*, P< 0.05 vs. untreated cells. (C) The FR4 or FR4D3 CDS was cloned directly into the pCI-neo vector and transiently transfected
into FACS-sorted CD4+CD25+ Tregs, followed by stimulation with or without combinations of FA, IL-2, and anti-CD3/anti-CD28 (pre-coated and
soluble, respectively). Wt represents no overexpression of either FR4 or FR4D3; FR4 represents the overexpression of FR4; FR4D3 represents the
overexpression of FR4D3. Panels show a representative of three independent experiments. Error bars represent the standard deviation from
triplicate wells. *, P< 0.05.
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identified particularly high expression in the nTregs T
cell subpopulation [13]. In our current study, we found
that FR4D3 was expressed in CD4+CD25+ Tregs at a
higher level than in either CD4+CD25- or CD8+ T cells,
suggesting that the expression of FR4D3 was cell type-
specific. Retroviral transduction of Foxp3, which can
functionally and phenotypically convert normal T cells
to natural Treg-like cells [22,23], has revealed that the
FR4 expression was proportional to that of Foxp3 in
Foxp3-transduced CD25-CD4+ T cells, suggesting that
Foxp3 can control, either directly or indirectly, the ex-
pression of FR4 in natural Treg cells [13]. Further re-
search is necessary to determine whether transduction
with Foxp3 is also sufficient to mediate FR4D3 up-
regulation.
As previously described for CD4+CD25+ Tregs, the
anergic state of a pure CD4+CD25+ Treg subpopulation
is abrogated after simultaneous stimulation of T cell
receptors (TCRs) and CD28 in the presence of IL-2; nei-
ther IL-2 nor plate-bound anti-CD3 combined with sol-
uble anti-CD28 could resolve the cells’ unresponsiveness
[24,25]. Furthermore, the capacity to efficiently bind and
incorporate folic acid is linked to cellular proliferation,
in both normal and tumorigenic conditions. In our
current study, we found that overexpressing FR4D3 or
FR4 in CD4+CD25+ Tregs could further enhance the
proliferation induced by FA, IL-2, and anti-CD3/anti-
CD28 (pre-coated and soluble, respectively) in vitro.
These results suggested that high expression of FR4D3
could facilitate binding of FA and cellular uptake, which
may be critical to support the substantial proliferative
capacity of Tregs in vivo. Of course, the FR4D3 may
have other yet unrecognized functions, which will re-
quire further investigation. We also found that the FA+
IL-2+ anti-CD3/anti-CD28 induced proliferative cap-
acity of CD4+CD25+ Tregs overexpressing FR4D3 was
weaker than in CD4+CD25+ Tregs overexpressing FR4.
These results suggested that the exon 3-related
sequences contribute to optimal FA binding and/or cel-
lular uptake mediated by FR4.
Conclusions
In conclusion, we have identified a novel exon 3-deleted
FR4 transcript variant, which encodes a 189 bp trun-
cated protein that is predominantly expressed in CD4
+CD25+ Treg cells. The high expression of FR4D3 in
CD4+CD25+ Tregs may modulate the ability of these
cells to bind and incorporate folic acid, possibly in nor-
mal or pathogenic conditions that would benefit from
enhanced proliferation of these cells.
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